Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial

被引：156

作者：

Vermorken, J. B. ^{[1
]}

Psyrri, A. ^{[2
]}

Mesia, R. ^{[3
]}

Peyrade, F. ^{[4
]}

Beier, F. ^{[5
]}

de Blas, B. ^{[6
]}

Celik, I. ^{[6
]}

Licitra, L. ^{[7
]}

机构：

[1] Univ Antwerp Hosp, Dept Med Oncol, B-2650 Edegem, Belgium

[2] Univ Athens Med Sch, Attikon Univ Hosp, Athens, Greece

[3] Hosp Llobregat, Catalan Inst Oncol, Dept Med Oncol, Barcelona, Spain

[4] Ctr Reg Lutte Canc Nice, Dept Oncohematol, Nice, France

[5] Merck KGaA, Global Biostat, Darmstadt, Germany

[6] Merck KGaA, Global Clin Dev Unit, Darmstadt, Germany

[7] Fdn IRCCS Ist Nazl Tumori, Dept Canc Med, Head & Neck Med Oncol Unit, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷 / 04期

关键词：

cetuximab; human papillomavirus; p16; recurrent and metastatic; squamous cell carcinoma of the head and neck; HUMAN-PAPILLOMAVIRUS; OROPHARYNGEAL CANCER; PHENOTYPE;

D O I：

10.1093/annonc/mdt574

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Adding cetuximab to chemotherapy improved survival in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Although HPV and p16 statuses have prognostic value, the observed survival benefit conferred by cetuximab is independent of both. This pattern remained in a combined analysis of both p16 and HPV and in patients with oropharyngeal cancer separately.Tumor human papillomavirus (HPV) status is an important prognostic factor in locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). Prognostic value in recurrent and/or metastatic (R/M) disease remains to be confirmed. This retrospective analysis of the EXTREME trial, comparing chemotherapy plus cetuximab with chemotherapy first line in R/M SCCHN, investigated efficacy and prognosis according to tumor p16 and HPV status. Paired tissue samples were used: p16INK4A expression was assessed by immunohistochemistry, and HPV status determined in extracted DNA samples using oligonucleotide hybridization assays. Altogether, 416 of 442 patients had tumor samples available for p16 and HPV: 10% of tumors were p16 positive and 5% were HPV positive. Adding cetuximab to chemotherapy improved survival, irrespective of tumor p16 or HPV status. This pattern remained in a combined analysis of p16 and HPV. p16 positivity and HPV positivity were associated with prolonged survival compared with p16 negativity and HPV negativity. Subgroup analysis of patients with oropharyngeal cancer demonstrated a similar pattern to all evaluable patients. The results from this analysis suggest that p16 and HPV status have prognostic value in R/M SCCHN and survival benefits of chemotherapy plus cetuximab over chemotherapy alone are independent of tumor p16 and HPV status.

引用

页码：801 / 807

页数：7